Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Type of study
Publication year range
1.
Stress ; 21(4): 370-375, 2018 07.
Article in English | MEDLINE | ID: mdl-29661114

ABSTRACT

Pasireotide is a new-generation somatostatin analog that acts through binding to multiple somatostatin receptor subtypes. Studies have shown that pasireotide induces hyperglycemia, reduces glucocorticoid secretion, alters neurotransmission, and potentially affects stress responses typically manifested as hyperglycemia and increased corticosterone secretion. This study specifically aimed to evaluate whether pasireotide treatment modifies glucose and costicosterone secretion in response to acute restraint stress. Male Holtzman rats of 150-200 g were treated with pasireotide (10 µg/kg/day) twice-daily for two weeks or vehicle for the same period. Blood samples were collected at baseline and after 5, 10, 30, and 60 min of restraint stress. The three experimental groups comprised of vehicle + restraint (VEHR), pasireotide + restraint (PASR), and pasireotide + saline (PASNR). Following pasireotide treatment, no significant differences in baseline glucose and corticosterone levels were observed among the three groups. During restraint, hyperglycemia was observed at 10 min (p < .01 for both comparisons), peaked at 30 min (p < .01 for both comparisons) and showed higher 60 min areas under glucose curves in the VEHR and PASR stressed groups when compared to the non-stressed PASNR group (p < .05 for both comparisons). Restraint also increased corticosterone secretion in the VEHR and PASR stressed groups at 5 min (p < .01 for both comparisons), and peaked at 30 min (p < .01 for both comparisons) with corresponding higher 60 min areas under corticosterone curves when compared to the non-stressed PASNR group (p < .01 for both comparisons). In conclusion, pasireotide treatment does not modify hyperglycemic- and corticosterone-restraint stress responses, thus preserving acute stress regulation.


Subject(s)
Blood Glucose/analysis , Corticosterone/blood , Somatostatin/analogs & derivatives , Stress, Physiological/drug effects , Animals , Male , Rats , Rats, Sprague-Dawley , Restraint, Physical , Somatostatin/pharmacology , Synaptic Transmission
2.
Rev. méd. Minas Gerais ; 23(1)jan.-mar. 2013.
Article in Portuguese, English | LILACS | ID: lil-702867

ABSTRACT

A adesão bacteriana aos biomateriais é processo de alta complexidade que demanda importante preocupação médica dada a sua evidente influência sobre a morbimortalidade dos pacientes que fazem uso de próteses, além dos vultosos gastos que o envolvem. Nesta revisão com base na literatura médica são apresentados os principais microrganismos envolvidos na adesão aos biomateriais, discutindo a patogênese desseprocesso, sendo abordada cada uma de suas etapas, inclusive a formação do biofilme, que é etapa ímpar para o estabelecimento da infecção. São indicados, também, os principais fatores que influenciam o mecanismo de adesão, incluindo as características bacterianas e dos materiais, assim como as propriedades do meio.


Bacterial adhesion to biomaterials is a highly complex process that warrants careful medical scrutiny given not only its obvious influence on morbidity and mortality of patients who use dentures, but also the substantial costs involved. In this literature-based review we present the main microorganisms involved in adhesion to biomaterials and discuss the pathogenesis involved, addressing each of its stages, including biofilm formation, which is a crucial step in the the establishment of infection. We also highlight the main factors influencing the adhesion mechanism, including bacterial, materials and medium properties.


Subject(s)
Humans , Bacterial Adhesion , Biofilms , Biocompatible Materials , Prostheses and Implants , Staphylococcus aureus/pathogenicity , Staphylococcus epidermidis/pathogenicity
3.
J. bras. med ; 101(1): 49-55, jan.-fev. 2013.
Article in Portuguese | LILACS | ID: lil-688979

ABSTRACT

Os leiomiomas uterinos são tumores monoclonais que se originam de uma mutação somática em um miócito progenitor. Representam a neoplasia benigna mais comum do útero. A causa precisa relacionada ao seu desenvolvimento ainda não foi totalmente esclarecida. As apresentações clínicas mais frequentes são o sangramento anormal, a dor e pressão pélvicas, massa pélvica não diagnosticada anteriormente e infertilidade. O diagnóstico baseia-se na história clínica, no exame físico, que pode ser completamente normal em alguns casos, e nos achados de exames complementares, como a ultrassonografia endovaginal, a histerossonografia e a ressonância magnética. O tratamento varia de acordo com a apresentação clínica e pode ser expectante, clínico ou cirúrgico.


The uterine leiomyomas are monoclonal tumors that originate from a somatic mutation in a myocyte progenitor and are the most common benign tumor of the uterus. The precise cause related to its development has not been fully clarified. The most common clinical presentations are abnormal vaginal bleeding, pelvic pain and pressure, previously undiagnosed pelvic mass, and infertility. The diagnosis is based on clinical history, physical examination, which may be completely normal in some cases, and the findings of laboratory tests such as transvaginal ultrasound, the sonohysterography, MRI. Treatment varies according to clinical presentation and may be expectant, medical or surgical.


Subject(s)
Humans , Female , Pregnancy , Anti-Inflammatory Agents, Non-Steroidal , Leiomyomatosis/therapy , Uterine Neoplasms/therapy , Aromatase Inhibitors , Uterine Artery Embolization , Hysterectomy , Gonadotropin-Releasing Hormone/analogs & derivatives , Leiomyoma/classification , Leiomyoma/epidemiology , Leiomyoma/etiology , Leiomyoma/physiopathology , Progesterone/administration & dosage , Selective Estrogen Receptor Modulators
SELECTION OF CITATIONS
SEARCH DETAIL
...